Brokers Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Zacks Research issued their FY2027 earnings estimates for shares of Intellia Therapeutics in a research note issued on Thursday, March 20th. Zacks Research analyst R. Department expects that the company will earn ($4.87) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Several other research analysts also recently issued reports on NTLA. BMO Capital Markets cut their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Chardan Capital reduced their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Barclays dropped their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Truist Financial reduced their target price on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, Wedbush reiterated a “neutral” rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $8.73 on Monday. The firm’s 50-day moving average is $10.05 and its two-hundred day moving average is $13.97. The company has a market capitalization of $903.70 million, a PE ratio of -1.60 and a beta of 1.97. Intellia Therapeutics has a 12-month low of $8.30 and a 12-month high of $28.23.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently bought and sold shares of NTLA. Wellington Management Group LLP raised its stake in shares of Intellia Therapeutics by 8.5% in the 4th quarter. Wellington Management Group LLP now owns 699,814 shares of the company’s stock valued at $8,160,000 after acquiring an additional 55,051 shares during the period. California State Teachers Retirement System raised its position in Intellia Therapeutics by 4.1% in the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after purchasing an additional 3,596 shares during the period. Polar Asset Management Partners Inc. lifted its stake in shares of Intellia Therapeutics by 1,144.1% during the fourth quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock worth $3,293,000 after purchasing an additional 259,700 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter worth about $25,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Intellia Therapeutics by 5.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock valued at $5,634,000 after buying an additional 23,173 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 29,000 shares of company stock worth $352,551 in the last three months. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.